CalciMedica’s lead candidate, Auxora^TM, is a proprietary, intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has been studied in four Phase 2 clinical trials, demonstrating positive and consistent efficacy as well as a favorable safety profile, and is currently being studied in two additional Phase 2 clinical studies.

Auxora^TM, has the potential to modulate the immune response and protect against tissue cell injury, addressing a high unmet need in inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure (AHRF) which currently have no approved therapies.